Results 31 to 40 of about 1,641 (192)

Resistance development in Escherichia coli to delafloxacin at pHs 6.0 and 7.3 compared to ciprofloxacin [PDF]

open access: yes, 2023
Understanding the resistance mechanisms of antibiotics in the micro-environment of the infection is important to assess their clinical applicability and potentially prevent resistance development.
Babouee Flury, Baharak   +5 more
core   +1 more source

In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 2016
ABSTRACT We evaluated the in vitro activity of delafloxacin against a panel of 117 Neisseria gonorrhoeae strains, including 110 clinical isolates collected from 2012 to 2015 and seven reference strains, compared with the activities of seven antimicrobials currently or previously ...
Olusegun O. Soge   +4 more
openaire   +2 more sources

In vitro Susceptibilities of Methicillin-Susceptible and Resistant Staphylococci to Traditional Antibiotics Compared to a Novel Fluoroquinolone

open access: yesJournal of Ophthalmic Inflammation and Infection, 2020
Background To assess the in-vitro efficacy of delafloxacin, a new fourth generation fluoroquinolone, against Staphylococcus vitreous isolates from patients with clinically diagnosed endophthalmitis.
Kenneth C. Fan   +8 more
doaj   +1 more source

Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model

open access: yesAntibiotics, 2023
Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant Pseudomonas aeruginosa (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and
Vaughn D. Craddock   +3 more
doaj   +1 more source

New antibiotics for multidrug-resistant bacterial strains: Latest research developments and future perspectives [PDF]

open access: yes, 2021
The present work aims to examine the worrying problem of antibiotic resistance and the emergence of multidrug-resistant bacterial strains, which have now become really common in hospitals and risk hindering the global control of infectious diseases ...
Pregnolato M., Taccani M., Terreni M.
core   +1 more source

New Antibiotics for Staphylococcus aureus Infection: An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA) [PDF]

open access: yes, 2023
Staphylococcus aureus is an extremely virulent pathogen that is capable of quickly evolving and developing antibiotic resistance. To overcome this problem, new antibiotics have been developed.
Bassetti M.   +11 more
core   +4 more sources

Targeting the hard to reach: Challenges and novel strategies in the treatment of intracellular bacterial infections: Targeting intracellular bacteria [PDF]

open access: yes, 2016
Infectious diseases continue to threaten human and animal health and welfare globally, impacting millions of lives and causing substantial economic loss. The use of antibacterials has been only partially successful in reducing disease impact.
Good, L, Kamaruzzaman, N F, Kendall, S L
core   +1 more source

Toxic medications in Charcot–Marie–Tooth patients: A systematic review

open access: yesJournal of the Peripheral Nervous System, Volume 28, Issue 3, Page 295-307, September 2023., 2023
Abstract Background and Aims Several widely used medications, with a relevant efficacy profile, are toxic to the peripheral nervous system and an even larger number of agents are suspected to be neurotoxic. There are concerns about the use of these drugs in patients with Charcot–Marie–Tooth disease (CMT), a hereditary motor and sensory neuropathy. This
Guido Cavaletti   +2 more
wiley   +1 more source

Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial

open access: yesInternational Journal of Infectious Diseases, 2020
Objectives: To report atypical pathogens from clinical trial data comparing delafloxacin to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia (CABP).
Sandra McCurdy   +6 more
doaj   +1 more source

Delafloxacin: First Global Approval [PDF]

open access: yesDrugs, 2017
Delafloxacin (Baxdela™) is a fluoroquinolone antibacterial with activity against both gram-positive and gram-negative pathogens being developed by Melinta Therapeutics. The drug is being investigated or considered as a treatment for various bacterial infections and in June 2017 received approval in the USA for the treatment of acute bacterial skin and ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy